Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025

Group 1 - The company Bright Minds Biosciences (NASDAQ: DRUG) is considered undervalued and has been initiated with a Buy rating [1] - A near-term catalyst for its primary asset, BMB-101, is expected in Q2 2025, which could drive value [1] - The company has a decent balance sheet and a significant market opportunity, indicating potential for growth [1]